BCC and cSCC: Bridging Dermatologic and Oncologic Perspectives on Management Controversies
Released On
June 27, 2025
Expires On
June 27, 2026
Media Type
Internet
Completion Time
30 minutes
Specialty
Dermatology, Hematology-Oncology
Topic(s)
Oncology, Skin Cancer
CME INFO
This activity is jointly provided by Partners for Advancing Clinical Education (Partners), and MedliveCME, LLC (previously known as PlatformQ Health Education, LLC).
Acknowledgement
This program is supported by an independent medical educational grant from Regeneron Pharmaceuticals, Inc.
Date of Release/Expiration
This activity was released on June 27th, 2025 and is valid until June 27th, 2026. Requests for credit must be made no later than June 27th, 2026.
Credit Available
Physicians - maximum of 0.5 AMA PRA Category 1 Credit™
Target Audience
The primary target audience for this activity are dermatologists, dermatologic oncologists, Mohs surgeons, surgical oncologists, medical oncologists, nurse practitioners, and physician assistants.
Program Overview
The management of patients with basal cell carcinoma (BCC) and cutaneous squamous cell carcinoma (cSCC) requires multi-modality treatment through multidisciplinary approaches, especially for more complex cases, including high-risk and recurrent disease. In addition, recent advances in immunotherapy can improve outcomes for patients with advanced BCC and advanced cSCC. Treatment options for patients with unresectable locally advanced or metastatic disease can be optimized when clinicians are up to date with the latest immunotherapies and guidelines. In the case of resectable disease, the use of immunotherapies can also be considered upon multidisciplinary consultation. In this three-module on-demand educational series, learn more about how to integrate evidence-based multi-modality therapies for BCC and cSCC, the efficacy and safety of immunotherapies to select the most appropriate therapy for each patient as well as the latest guidelines for BCC and cSCC management and adverse events associated with immunotherapy. An on-demand activity with expert commentary from Dr. James Grichnik, Dr. Lilia Correa, and Dr. Nikhil Khushalani will discuss clinical controversies, highlight modules 1-3 and review expert multidisciplinary approaches.
Educational Objectives
After completing this activity, the participant should be better able to:
- Consider key clinical controversies in BCC and cSCC and review expert multidisciplinary approaches
Joint Accreditation Statement
In support of improving patient care, this activity has been planned and implemented by Partners for Advancing Clinical Education (Partners) and MedliveCME, LLC (previously known as PlatformQ Health Education, LLC). Partners is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Physician Continuing Education
Partners designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Estimated Time to Complete
This activity should take approximately 30 minutes to complete.
Instructions to Receive Credit
In order to receive credit for this activity, the participant must (1) read the target audience, learning objectives, and disclosure statements, (2) complete the educational activity online, and (3) complete the post-test and activity evaluation. TO receive AMA PRA Category 1 Credits™, participants must receive a score of 75% on the post-test.
Hardware/Software Requirements
Participants will need a computer with a recent version of Adobe Flash installed, as well as an internet connection sufficient for streaming media.
Fee Information & Refund/Cancellation Policy
There is no fee for this educational activity.
Disclosures of Relevant Financial Relationships
Partners requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.
All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated according to Partners policies. Others involved in the planning of this activity have no relevant financial relationships.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Contact Information
Accreditation Support
For additional information about the accreditation of this activity, please visit https://partnersed.com.
Technical Support
For any technical issues or issues with your CME Certificate, please contact MedLive at 877-394-1306 or at [email protected].
PlatformQ Health Privacy Policy
By clicking “Start Activity” you are agreeing to PlatformQ Health’s privacy policy. PlatformQ Health takes your privacy very seriously. The full Privacy Policy found here (i) the types of information we collect from you when you visit our Site; (ii) how we use the information we collect; (iii) with whom and why we share it; and (iv) the choices we offer regarding our use of the information. We also describe how to contact us about our privacy practices.
Information we collect is primarily used to communicate with program participants, award CME/CE credits, manage user accounts, recommend relevant programs and perform data analysis to inform educational outcomes.
In plain English, here is what we affirm:
- You can change your registration profile at any time from our “Profile” page
- To request any of these changes without logging in, please call us at 1 (877) 394-1306 or email us at [email protected]
- You can end your association with PlatformQ Health at any time
- PlatformQ Health does not spam, nor we do we rent or sell our email list in whole or in part. Any program-related data sharing is for engagement verification and opt-in based further education
- EU citizens can request a complete record of their account and/or request to have their personal data expunged by contacting [email protected] with the subject line “Data Request”
You acknowledge and agree that by beginning this activity, you have affirmatively agreed to this Privacy Policy and consented to receiving electronic messages in conformance with this Privacy Policy. Please read the full privacy policy located at: www.platformqhealth.com/privacy-policy/